{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:00:58Z","timestamp":1772006458445,"version":"3.50.1"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune-mediated inflammatory diseases (IMIDs) often affect women of childbearing age. Since active inflammatory disease is related with impaired reproductive outcomes, effective disease control is crucial. Clinical guidelines aim to support evidence-based shared decision-making. However, inconsistencies between guidelines across specialties may cause confusion, undermine adherence and lead to adverse health outcomes. This study aimed to assess consistency within and across perinatal IMID guidelines in gastroenterology, rheumatology and dermatology regarding medication use during pregnancy, lactation and among prospective fathers, and to identify medications with insufficient safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review was conducted in August 2025 using most recent versions of leading international guidelines (N = 11), published between 2015 and 2025. Guideline recommendations for IMID medications were categorized by two independent authors. Data-analysis examined the prevalence and type of consistency, trimester-specific consistency, most common recommendation per medication and the agreement on preconception discontinuation timing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within medical specialties, guideline consistency for individual medications was highest for gastroenterology (61\/74, 82.4%), followed by rheumatology (165\/220, 75.0%) and dermatology (57\/94, 60.6%). Across specialties, agreement was greatest between gastroenterology and rheumatology (pregnancy 86.2%, lactation 81.2%, paternal 88.5%) and lowest between gastroenterology and dermatology (pregnancy 51.3%, lactation 40.6%, paternal 47.1%). Trimester-specific recommendations were consistent across guidelines in 33.3% (2\/6) of the cases. Agreement on preconception discontinuation timing was 41.7% (5\/12) for maternal cases and 66.7% (2\/3) for paternal exposure. At least one inconsistency was found in 75.0% of within-guideline and 87.5% of across-guideline comparisons. At medication-class level, most inconsistencies stemmed from insufficient safety data reporting (59.5%), particularly for small molecules (28.6%), immunomodulators (26.1%) and interleukin inhibitors (34.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inconsistencies between guidelines, both within and across specialties, were frequent and pose challenges for reproductive decision-making in IMID patients. The lack of safety data in reproductive contexts contributed to guideline inconsistencies and revealed the need to prioritize future research on recently marketed pharmacotherapeutic classes, such as small molecules (JAK-inhibitors, PDE4-modulators) and interleukin inhibitors. In the future, guidelines should be updated regularly, include explicit recommendations, integrate reproductive contexts, and adopt unambiguous language, standardized categories and uniform methodological frameworks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1744957","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:04:45Z","timestamp":1772003085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Inconsistent medication recommendations for immune-mediated inflammatory diseases across pregnancy, lactation, and paternal preconception: a guideline-based review"],"prefix":"10.3389","volume":"17","author":[{"given":"Elise","family":"Van den Broeck","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sien","family":"Lenie","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospitals Leuven","place":["Leuven, Belgium"]},{"name":"Department of Chronic Diseases and Metabolism, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"De Langhe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Leuven","place":["Leuven, Belgium"]},{"name":"Department of Development and Regeneration, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Neerinckx","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Leuven","place":["Leuven, Belgium"]},{"name":"Department of Development and Regeneration, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Hillary","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Leuven","place":["Leuven, Belgium"]},{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristel","family":"Van Calsteren","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, KU Leuven","place":["Leuven, Belgium"]},{"name":"Department of Gynecology and Obstetrics, University Hospitals Leuven, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Smits","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, KU Leuven","place":["Leuven, Belgium"]},{"name":"Neonatal Intensive Care Unit, University Hospitals Leuven","place":["Leuven, Belgium"]},{"name":"L-C&Y, KU Leuven Child & Youth Institute","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Sillis","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven","place":["Leuven, Belgium"]},{"name":"L-C&Y, KU Leuven Child & Youth Institute","place":["Leuven, Belgium"]},{"name":"Research Foundation Flanders (FWO)","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Julsgaard","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital","place":["Aarhus, Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University","place":["Aarhus, Denmark"]},{"name":"Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University","place":["Copenhagen, Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Foulon","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven","place":["Leuven, Belgium"]},{"name":"L-C&Y, KU Leuven Child & Youth Institute","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ceulemans","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven","place":["Leuven, Belgium"]},{"name":"L-C&Y, KU Leuven Child & Youth Institute","place":["Leuven, Belgium"]},{"name":"Research Foundation Flanders (FWO)","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2532676","DOI":"10.1080\/09546634.2025.2532676","article-title":"Family planning and pregnancy among patients with psoriasis: incorporating the patients' voice in healthcare practice and information provision","volume":"36","author":"Barenbrug","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"B2","doi-asserted-by":"publisher","first-page":"621247","DOI":"10.3389\/fphar.2021.621247","article-title":"Biologics during pregnancy and breastfeeding among women with rheumatic diseases: safety clinical evidence on the road","volume":"12","author":"Beltagy","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajog.2021.02.002","article-title":"Obstetrical, fetal, and lactation pharmacology-a crisis that can no longer be ignored","volume":"225","author":"Caritis","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/ueg2.70122","article-title":"International survey of gastroenterologists on managing inflammatory bowel disease during pregnancy and lactation: Current state and the necessity for improvements","volume":"13","author":"Casanova","year":"2025","journal-title":"United Eur. Gastroenterol. J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003593","article-title":"Birth outcomes in women who have taken vedolizumab in pregnancy: results from the vedolizumab pregnancy exposure registry","author":"Chambers","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1001\/jamadermatol.2023.1400","article-title":"Fertility trends and adverse pregnancy outcomes in female patients with psoriasis in the UK","volume":"159","author":"Chen","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/intqhc\/mzl007","article-title":"From outdated to updated, keeping clinical guidelines valid","volume":"18","author":"Clark","year":"2006","journal-title":"Int. J. Qual. Health Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf."},{"key":"B9","first-page":"146","article-title":"A model of ambiguity and vagueness in clinical practice guideline recommendations","volume":"2005","author":"Codish","year":"2005","journal-title":"AMIA Annu. Symp. Proc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and crohn's disease: 4 years of global post-marketing data","volume":"14","author":"Cohen","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.3390\/jcm14082644","article-title":"The development of a multidisciplinary care pathway for patients with inflammatory bowel disease before, during and after pregnancy","volume":"14","author":"De Dycker","year":"2025","journal-title":"J. Clin. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1093\/ibd\/izae011","article-title":"Pregnancy outcomes in the ozanimod clinical development program in patients with ulcerative colitis, Crohn's disease, and relapsing multiple sclerosis","volume":"30","author":"Dubinsky","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S1542-3565(25)00526-9","DOI":"10.1016\/j.cgh.2025.06.007","article-title":"Upadacitinib in mothers with inflammatory bowel disease: placental transfer and breast milk excretion","author":"Duricova","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae006","article-title":"Normal infant immunologic assessment and uneventful live rotavirus vaccination despite continuous tofacitinib exposure in utero and during breastfeeding","volume":"6","author":"Ernest-Suarez","year":"2024","journal-title":"Crohns Colitis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cgh.2024.07.007","article-title":"Live rotavirus vaccination appears low-risk in infants born to mothers with inflammatory bowel disease on biologics","volume":"23","author":"Ernest-Suarez","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B16","unstructured":"EMA recommends additional measures to prevent use of mycophenolate in pregnancy 2015\n          \n          \n          2015"},{"key":"B17","unstructured":"Mycophenolate: updated recommendations for contraception for men and women\n          \n          \n          2017"},{"key":"B18","unstructured":"Recent letter by ENTIS members questions the EMA warning on paternal use of mycophenolate mofetil 2016\n          \n          \n          2016"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2510504","DOI":"10.1001\/jamanetworkopen.2025.10504","article-title":"Use of biologics during pregnancy among patients with autoimmune conditions","volume":"8","author":"Ewig","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"107792","DOI":"10.1016\/j.phrs.2025.107792","article-title":"Pediatric infections in the first year of life following maternal biologic exposure for autoimmune disorder treatment: a systematic review","volume":"217","author":"Fajardo","year":"2025","journal-title":"Pharmacol. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40264-023-01384-3","article-title":"Improving data collection in pregnancy safety studies: towards standardisation of data elements in pregnancy reports from public and private partners, A contribution from the ConcePTION project","volume":"47","author":"Favre","year":"2024","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/ibd\/izae132","article-title":"Paternal inflammatory bowel disease and the risk of pregnancy loss","volume":"31","author":"Friedman","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/ajo.13940","article-title":"The effect of assisted reproductive technologies on human sex ratios","volume":"65","author":"Georgiou","year":"2025","journal-title":"Aust. N. Z. J. Obstet. Gynaecol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bcp.14145","article-title":"The pre- and post-authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation","volume":"86","author":"Ghalandari","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1002\/bcp.70139","article-title":"Prescription drug use in breastfeeding mothers and infant exposure: a register-based cohort study","volume":"91","author":"Gotfredsen","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1053\/j.gastro.2019.02.041","article-title":"Vedolizumab does not impair sperm DNA integrity in men with inflammatory bowel disease","volume":"156","author":"Grosen","year":"2019","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1093\/ibd\/izac028","article-title":"Normal sperm DNA integrity in patients with inflammatory bowel disease on ustekinumab maintenance therapy","volume":"28","author":"Grosen","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/rheumatology\/ker302","article-title":"Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use","volume":"50","author":"Hazes","year":"2011","journal-title":"Rheumatol. Oxf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/1346-8138.15658","article-title":"Fetal-neonatal and maternal outcomes in women with psoriasis vulgaris: a nationwide population-based registry linkage study in Taiwan","volume":"48","author":"Huang","year":"2021","journal-title":"J. Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.34172\/mejdd.2023.350","article-title":"Pregnancy and inflammatory bowel disease: a special combination. Middle East","volume":"15","author":"Izquierdo","year":"2023","journal-title":"J. Dig. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00228-024-03790-7","article-title":"The quantity, reliability, transparency, reporting, and interpretation of pharmacovigilance signal detection studies in pregnancy: a meta-epidemiological study","volume":"81","author":"Jiao","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/14740338.2021.1873948","article-title":"Use of medications during pregnancy and breastfeeding for crohn's disease and ulcerative colitis","volume":"20","author":"Laube","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"103827","DOI":"10.1016\/j.autrev.2025.103827","article-title":"Safety of biologics in patients with autoimmune rheumatic diseases during pregnancy: systematic review and meta-analysis","volume":"24","author":"Li","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/apt.13960","article-title":"Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease","volume":"45","author":"Mahadevan","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/apt.16960","article-title":"Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: review of cases reported to the manufacturer's global safety database","volume":"56","author":"Mahadevan","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","article-title":"Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports","volume":"47","author":"Mahadevan","year":"2024","journal-title":"Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/ibd\/izaf171","article-title":"Global consensus statement on the management of pregnancy in inflammatory bowel diseases","volume":"31","author":"Mahadevan","year":"","journal-title":"Gut"},{"key":"B39","doi-asserted-by":"publisher","first-page":"jjaf129","DOI":"10.1093\/ecco-jcc\/jjaf129","article-title":"Global consensus statement on the management of pregnancy in inflammatory bowel disease","volume":"19","author":"Mahadevan","year":"","journal-title":"J. Crohns Colitis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1186\/s12884-024-06932-y","article-title":"Trends in medications for autoimmune disorders during pregnancy and factors for their discontinuation: a population-based study","volume":"24","author":"Mainbourg","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"B41","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/annrheumdis-2020-218356","article-title":"EULAR recommendations for a core data set for pregnancy registries in rheumatology","volume":"80","author":"Meissner","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American academy of Dermatology-national Psoriasis foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1007\/s00431-024-05683-4","article-title":"Serological responses to vaccination in children exposed in utero to ustekinumab or vedolizumab: cross-sectional analysis of a prospective multicentre cohort","volume":"183","author":"Mitrova","year":"2024","journal-title":"Eur. J. Pediatr."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.01.019","article-title":"Tofacitinib in pregnancy: assessing pregnancy and infant outcomes, cord blood, and breast milk concentrations","volume":"23","author":"Mitrova","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/jcm13010034","article-title":"Reproductive safety issues of novel small molecules for the treatment of inflammatory bowel disease: a systematic review","volume":"13","author":"Monfared","year":"2023","journal-title":"J. Clin. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"103301","DOI":"10.1016\/j.jaut.2024.103301","article-title":"Safety of biologic immunosuppressants in pregnant women with immune-mediated inflammatory diseases","volume":"148","author":"N","year":"2024","journal-title":"J. Autoimmun."},{"key":"B49","article-title":"EUROGUIDERM guideline for the systemic treatment of psoriasis vulgaris","author":"Nast","year":"2023","journal-title":"Eur. Dermatol. Forum (EDF)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1080\/14740338.2021.1935865","article-title":"Online information discrepancies regarding safety of medicine use during pregnancy and lactation: an IMI ConcePTION study","volume":"20","author":"N\u00f6rby","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.sxmr.2020.07.004","article-title":"Male sexual health and reproduction in cutaneous immune-mediated diseases: a systematic review","volume":"9","author":"Perez-Garcia","year":"2021","journal-title":"Sex. Med. Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13006-025-00756-y","article-title":"The effect of medication use on breastfeeding continuation: a systematic review with narrative synthesis","volume":"20","author":"Pilgrim","year":"2025","journal-title":"Int. Breastfeed. J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2025.03.016","article-title":"Active inflammatory bowel disease on intestinal ultrasound during pregnancy is associated with an increased risk of adverse pregnancy and neonatal outcomes independent of clinical and biochemical disease activity","volume":"169","author":"Prentice","year":"","journal-title":"Gastroenterology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2024.02.025","article-title":"Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero","volume":"23","author":"Prentice","year":"","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-023-01291-7","article-title":"Core data elements for pregnancy pharmacovigilance studies using primary source data collection methods: recommendations from the IMI ConcePTION project","volume":"46","author":"Richardson","year":"2023","journal-title":"Drug Saf."},{"key":"B56","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40264-022-01154-7","article-title":"A landscape analysis of post-marketing studies registered in the EU PAS register and clinicalTrials.gov focusing on pregnancy outcomes or breastfeeding effects: a contribution from the ConcePTION project","volume":"45","author":"Roque","year":"2022","journal-title":"Drug Saf."},{"key":"B57","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ard.2025.02.023","article-title":"EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update","volume":"84","author":"R\u00fcegg","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British society for rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatol. Oxf."},{"key":"B59","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.41191","article-title":"American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1759720x251350087","DOI":"10.1177\/1759720X251350087","article-title":"Impact of conflicting information on the use of antirheumatic drugs in pregnancy and breastfeeding: perspectives of healthcare providers from the global PRAISE survey","volume":"17","author":"Schreiber","year":"2025","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.3390\/ijerph19074248","article-title":"Experiences and perspectives of marketing authorisation holders towards medication safety monitoring during pregnancy: a pan-European qualitative analysis","volume":"19","author":"Sillis","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European crohn's and colitis guidelines on sexuality, fertility, pregnancy, and lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/jdv.15709","article-title":"European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period","volume":"33","author":"Vestergaard","year":"2019","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/08903344251337384","article-title":"Lower adherence to breastfeeding recommendations in mothers treated with antirheumatic and antidepressant medications","volume":"41","author":"Whaites","year":"2025","journal-title":"J. Hum. Lact."},{"key":"B65","volume-title":"EUROGUIDERM guideline on atopic Eczema \u2013 version 3.0","author":"Wollenberg","year":"2025"},{"key":"B66","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol Venereol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1744957\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:04:48Z","timestamp":1772003088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1744957\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":66,"alternative-id":["10.3389\/fphar.2026.1744957"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1744957","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1744957"}}